Zachary Clark

Dr. Zachary Clark

orcid

Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
3 March 2026 in Cancers
Verified
Journal Article
Open access
PDF file
IPIrina Pushel
Irina Pushel
ZCZachary Clark
Zachary Clark
LLLisa A. Lansdon
Lisa A. Lansdon
BYByunggil Yoo
Byunggil Yoo
MRMichaella J Rekowski
Michaella J Rekowski
MFMidhat Farooqi
Midhat Farooqi
Background/Objectives: Molecular subtyping of pediatric B-cell acute lymphoblastic leukemia (B-ALL) has improved patient outcomes through stratification and selection of targeted therapies. Despite extensive genomic and transcriptomic profiling of this cancer, few studies to date have characterized the proteomic landscape, although proteins are the direct targets of many therapeutic agents. Methods: In this study, we demonstrate the utility of multi-omic integration of global transcriptomic, proteomic, and phosphoproteomic profiles of samples from patients diagnosed with either of two B-ALL subtypes—Ph-like (BCR::ABL1-like) and ETV6::RUNX1. Through individual and multi-omic analysis, we recapitulate known transcriptomic findings and identify novel subtype-specific proteomic and phosphoproteomic biomarkers. Conclusions: Our findings suggest a previously undescribed role for calcium-dependent signaling processes in Ph-like B-ALL, which has the potential to serve as a novel avenue for targeted treatments. By integrating multiple -omics modalities, we identify not only features of interest but also begin to unravel the regulatory interactions driving subtype-specific mechanisms of leukemogenesis. This integrated analytic approach paves the way for enhanced precision medicine for precise subtyping and treatment selection for pediatric leukemia patients.

18 September 2026 in Angewandte Chemie International Edition
Verified
Journal Article
Open access
PDF file
MRMatthew C. Russolillo
Matthew C. Russolillo
WNWariya Nirachonkul
Wariya Nirachonkul
NRNora Ross
Nora Ross
RHRahul M. Hedau
Rahul M. Hedau
ZCZachary Clark
Zachary Clark
Mark P. FarrellMark P. Farrell
Mark P. Farrell
Weak and transient carbohydrate–protein interactions hinder the detection of carbohydrate‐binding proteins (CBPs) in native settings. Here, we introduce carbohydrate‐directed labeling probes (CDLPs), modular ligand‐directed covalent probes composed of a glycan ligand, an acyl‐transfer electrophile, and a distal azide handle. Glycan binding positions the electrophile for proximity‐enhanced, glycan‐releasing acyl transfer, leaving an azide‐bearing acyl tag on the protein. Benchmark CDLPs capture carbohydrate–protein interactions with monovalent K D values extending into the millimolar range. In Daudi B cells, a 6′‐sialyllactose CDLP preferentially captures CD22 (Siglec‐2), demonstrating glycan‐dependent labeling in live cells. Quantitative chemoproteomics using 6′‐sialyllactose‐ and lactose‐CDLPs yields complementary competition‐sensitive CDLP‐capture profiles (6′SL‐CDLP: 95; Lac‐CDLP: 113; 21 shared), including canonical CBPs, glycan‐processing proteins, and candidate proteins lacking prior glycan‐related annotations. CDLPs provide an accessible, UV‐independent route to durable covalent readouts for targeted validation and proteome‐scale candidate discovery.

2 December 2024 in bioRxiv
Verified
Preprint
Open access
PDF file
PGPratik Goswami
Pratik Goswami
JCJoseph Cesare
Joseph Cesare
MRMichaella J. Rekowski
Michaella J. Rekowski
ZCZachary Clark
Zachary Clark
JTJanet Thornton
Janet Thornton
MWMichael P. Washburn
Michael P. Washburn
In this study, we analyzed the combination of affinity purification mass spectrometry (AP-MS) with high-field asymmetric waveform ion mobility spectrometry (FAIMS), integrated between nanoLC-MS and an Orbitrap Ascend Tribrid Mass Spectrometer. Our primary objective was to evaluate the application of the FAIMS interface for detecting affinity purified SAP25 protein complexes with enhanced sensitivity and robustness. As a result, we observed that nanoLC-FAIMS-MS (with FAIMS) significantly improved the sensitivity and detection limits at the protein level, peptide level and significantly reduced chemical contaminants compared to nanoLC-MS alone without FAIMS (No FAIMS). This FAIMS configuration resulted in 42% and 92% increases for the total proteins and unique proteins, respectively, and 44% and 88% increases for total peptides and unique peptides compared to the No FAIMS configuration. Our in-depth comparison of FAIMS and No FAIMS shows that FAIMS outperforms by significantly reducing the missing value by <15% in datasets and plays a significant role in filtering chemical contaminants. Our findings highlight the potential of FAIMS with Orbitrap Ascend Tribrid Mass Spectrometer to enhance the depth of AP-MS analysis. The data were deposited with the MASSIVE repository with the identifier MSV000096548.

17 August 2025 in bioRxiv
Verified
Preprint
Open access
IPIrina Pushel
Irina Pushel
ZCZachary Clark
Zachary Clark
LLLisa A Lansdon
Lisa A Lansdon
BYByunggil Yoo
Byunggil Yoo
MRMichaella J Rekowski
Michaella J Rekowski
MFMidhat Farooqi
Midhat Farooqi
Molecular subtyping of pediatric B-cell acute lymphoblastic leukemia (B-ALL) has improved patient outcomes through stratification and selection of targeted therapies. Despite extensive genomic and transcriptomic profiling of this cancer, few studies to date have characterized the proteomic landscape, although proteins are the direct targets of many therapeutic agents. In this study, we demonstrate the utility of multi-omic integration of global transcriptomic, proteomic, and phosphoproteomic profiles of samples from patients diagnosed with either of two B-ALL subtypes – Ph- like ( BCR::ABL1 -like) and ETV6::RUNX1 . Through individual and multi-omic analysis, we recapitulate known transcriptomic findings and identify novel subtype-specific proteomic and phosphoproteomic biomarkers. Our findings suggest a previously undescribed role for calcium-dependent signaling processes in Ph-like B-ALL, which has the potential to serve as a novel avenue for targeted treatments. By integrating multiple ‘omics modalities, we identify not only features of interest but also begin to unravel the regulatory interactions driving subtype-specific mechanisms of leukemogenesis. This integrated analytic approach paves the way for enhanced precision medicine for precise subtyping and treatment selection for pediatric leukemia patients. Mass spectrometry data generated in this study have been deposited in MassIVE under accession MSV000097955.

6 June 2026 in bioRxiv
Verified
Preprint
Open access
TMThuraya M. Mutawi
Thuraya M. Mutawi
SMShweta R. Malvankar
Shweta R. Malvankar
AGAndrea Graziani
Andrea Graziani
USUdita Shah
Udita Shah
KNKhanh Nguyen
Khanh Nguyen
CBCarlo Barnaba
Carlo Barnaba
Metformin is the most widely prescribed antidiabetic drug and an active candidate for repurposing in oncology. How it engages autophagy – a pathway central to both its metabolic and its anti-tumor effects – has remained unresolved, with reports of induction, suppression, and no effect. Here we show that metformin reroutes rather than induces or inhibits autophagy in human cancer cells: at therapeutic concentrations, it suppresses bulk cytosolic turnover by selectively blocking WIPI2-mediated phagophore tethering, while the ULK1 initiation complex relocates toward mitochondria and engages selective mitochondrial clearance. We trace this redirection to mitochondrial complex I inhibition, registered as a shift in the NAD + /NADH ratio before any change in the adenylate pool, and to a non-canonical reprogramming of the ULK1 complex that operates independently of mTORC1 and of the proposed PEN2-lysosomal route. AMPK is engaged in a subunit-specific manner that restrains ATG13 at initiation and enables WIPI2 displacement at maturation. The ULK1 complex is therefore the node at which metformin sets autophagic substrate selection, with direct implications for combination therapy in diabetes and cancer.

18 September 2026 in Angewandte Chemie
Verified
Journal Article
Open access
PDF file
MRMatthew C. Russolillo
Matthew C. Russolillo
WNWariya Nirachonkul
Wariya Nirachonkul
NRNora Ross
Nora Ross
RHRahul M. Hedau
Rahul M. Hedau
ZCZachary Clark
Zachary Clark
Mark P. FarrellMark P. Farrell
Mark P. Farrell
Weak and transient carbohydrate–protein interactions hinder the detection of carbohydrate‐binding proteins (CBPs) in native settings. Here, we introduce carbohydrate‐directed labeling probes (CDLPs), modular ligand‐directed covalent probes composed of a glycan ligand, an acyl‐transfer electrophile, and a distal azide handle. Glycan binding positions the electrophile for proximity‐enhanced, glycan‐releasing acyl transfer, leaving an azide‐bearing acyl tag on the protein. Benchmark CDLPs capture carbohydrate–protein interactions with monovalent K D values extending into the millimolar range. In Daudi B cells, a 6′‐sialyllactose CDLP preferentially captures CD22 (Siglec‐2), demonstrating glycan‐dependent labeling in live cells. Quantitative chemoproteomics using 6′‐sialyllactose‐ and lactose‐CDLPs yields complementary competition‐sensitive CDLP‐capture profiles (6′SL‐CDLP: 95; Lac‐CDLP: 113; 21 shared), including canonical CBPs, glycan‐processing proteins, and candidate proteins lacking prior glycan‐related annotations. CDLPs provide an accessible, UV‐independent route to durable covalent readouts for targeted validation and proteome‐scale candidate discovery.